Princeton -
Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of infections caused by Gram-positive bacteria and is the generic version of Cubicin. Fosaprepitant is an antiemetic drug used in the prevention of nausea and vomiting associated with certain chemotherapies, administered as IV infusion, and is the generic prodrug of Emend for injection.
'These medicines strategically support our institutional portfolio, add value for our sales force, and increase our overall offerings in the hospital setting,' said
Under the distribution and supply agreements,
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'seek,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the daptomycin and fosaprepitant products or regarding the transaction described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the expected benefits and synergies from the transaction will be achieved in the expected timeframe, or at all. In particular, our expectations regarding the transaction and such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit
About
Contact:
Tel: +41 79 7233681
Email: antonio.ligi@novartis.com
(C) 2020 Electronic News Publishing, source